CU20130057A7 - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents

Polipéptidos del factor ix modificados y usos de los mismos

Info

Publication number
CU20130057A7
CU20130057A7 CU2013000057A CU20130057A CU20130057A7 CU 20130057 A7 CU20130057 A7 CU 20130057A7 CU 2013000057 A CU2013000057 A CU 2013000057A CU 20130057 A CU20130057 A CU 20130057A CU 20130057 A7 CU20130057 A7 CU 20130057A7
Authority
CU
Cuba
Prior art keywords
polipeptides
same
modified factor
factor
modified
Prior art date
Application number
CU2013000057A
Other languages
English (en)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130057(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20130057A7 publication Critical patent/CU20130057A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a procedimientos para producir polipéptidos del Factor IX modificados.
CU2013000057A 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos CU20130057A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CU20130057A7 true CU20130057A7 (es) 2013-06-28

Family

ID=43529743

Family Applications (3)

Application Number Title Priority Date Filing Date
CU20120018A CU20120018A7 (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos
CU2013000057A CU20130057A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos
CU2013000058A CU20130058A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CU20120018A CU20120018A7 (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CU2013000058A CU20130058A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (es)
EP (1) EP2461821A4 (es)
JP (1) JP2013500726A (es)
KR (1) KR20120060209A (es)
CN (1) CN102573890A (es)
AU (1) AU2010278721A1 (es)
BR (1) BR112012002072A2 (es)
CA (1) CA2769258A1 (es)
CL (1) CL2012000238A1 (es)
CR (1) CR20120052A (es)
CU (3) CU20120018A7 (es)
DO (1) DOP2012000030A (es)
EA (1) EA201290069A1 (es)
EC (1) ECSP12011637A (es)
GT (1) GT201200023A (es)
IN (1) IN2012DN00908A (es)
MX (1) MX2012001346A (es)
PE (1) PE20121643A1 (es)
SG (1) SG178119A1 (es)
WO (1) WO2011014890A1 (es)
ZA (1) ZA201200716B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
AU2011282571C1 (en) * 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
CA2856492C (en) * 2011-12-19 2017-01-10 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
US10105447B2 (en) * 2013-03-13 2018-10-23 Elanco Us Inc. Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
BR112021007301A2 (pt) 2018-10-18 2021-07-27 Intellia Therapeutics, Inc. composições e métodos para expressar fator ix

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086091A2 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
GT201200023A (es) 2014-01-27
CU20130058A7 (es) 2013-06-28
KR20120060209A (ko) 2012-06-11
CU20120018A7 (es) 2012-06-21
WO2011014890A1 (en) 2011-02-03
IN2012DN00908A (es) 2015-04-03
CN102573890A (zh) 2012-07-11
AU2010278721A1 (en) 2012-02-16
EP2461821A4 (en) 2013-07-03
SG178119A1 (en) 2012-03-29
JP2013500726A (ja) 2013-01-10
EA201290069A1 (ru) 2012-07-30
CA2769258A1 (en) 2011-02-03
CL2012000238A1 (es) 2012-10-05
MX2012001346A (es) 2012-02-17
CR20120052A (es) 2012-06-04
ECSP12011637A (es) 2012-02-29
EP2461821A1 (en) 2012-06-13
ZA201200716B (en) 2013-07-31
PE20121643A1 (es) 2012-11-25
DOP2012000030A (es) 2012-02-29
US20120164130A1 (en) 2012-06-28
BR112012002072A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
CU20130058A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
PA8836801A1 (es) Polipeptidos g-csf de bovino modificados y sus usos
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
UY34538A (es) Heteroarilos y usos de los mismos
HN2010000084A (es) Derivados de sulfonamida
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
UY34472A (es) Derivados modificados de 4-fenil-piridina
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
PL2324831T3 (pl) Terapia pirfenidonem z wykluczeniem fluwoksaminy
BR112013028512A2 (pt) cápsula
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
CL2009001624S1 (es) Maquina para preparar bebidas.
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112015012907A2 (pt) composição de cuidado pessoal
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
DK2533895T3 (da) Fremgangsmåde til fremstilling af hydrogeneret biodiesel
UY34018A (es) Derivados glucósidos y usos de los mismos
GT201000031S (es) Diseño de confitería
BR112013028039A2 (pt) composição de cimento
CR20140124A (es) Metabolitos de transclomifeno y usos de los mismos
UY34670A (es) Planta para la producción de peróxido de hidrógeno y proceso para su uso